Kane Biotech Announces Third Quarter 2024 Financial Results
Kane Biotech reports significant Q3 2024 financial results, marking its first commercial sale of revyve™ Wound Gel. Total revenue reached $1,282,698, up from $27,003 in Q3 2023, with product sales of $597,677 and product services revenue of $685,021. Gross profit increased to $558,754, while net loss decreased 45% to $(678,636). The company secured multiple distribution agreements, received Health Canada approval for revyve™ Antimicrobial Wound Gel, and announced plans to acquire FB Dermatology. Additionally, Kane received MDSAP certification and was awarded NRC IRAP funding totaling $275,000 for research and development projects.
Kane Biotech riporta risultati finanziari significativi per il terzo trimestre del 2024, segnando la sua prima vendita commerciale del revyve™ Wound Gel. Il fatturato totale ha raggiunto 1.282.698 dollari, in aumento rispetto ai 27.003 dollari del terzo trimestre del 2023, con vendite di prodotti pari a 597.677 dollari e ricavi da servizi di prodotto di 685.021 dollari. Il profitto lordo è aumentato a 558.754 dollari, mentre la perdita netta è diminuita del 45%, arrivando a $(678.636). L'azienda ha ottenuto numerosi accordi di distribuzione, ha ricevuto l'approvazione di Health Canada per il revyve™ Antimicrobial Wound Gel e ha annunciato piani per acquisire FB Dermatology. Inoltre, Kane ha ricevuto la certificazione MDSAP ed è stata premiata con un finanziamento NRC IRAP di 275.000 dollari per progetti di ricerca e sviluppo.
Kane Biotech informa sobre resultados financieros significativos en el tercer trimestre de 2024, marcando su primera venta comercial del revyve™ Wound Gel. Los ingresos totales alcanzaron los 1.282.698 dólares, un aumento desde los 27.003 dólares en el tercer trimestre de 2023, con ventas de productos de 597.677 dólares y ingresos por servicios de productos de 685.021 dólares. La ganancia bruta aumentó a 558.754 dólares, mientras que la pérdida neta disminuyó un 45%, alcanzando los $(678.636). La compañía aseguró múltiples acuerdos de distribución, recibió la aprobación de Health Canada para el revyve™ Antimicrobial Wound Gel y anunció planes para adquirir FB Dermatology. Además, Kane obtuvo la certificación MDSAP y recibió financiamiento NRC IRAP por un total de 275.000 dólares para proyectos de investigación y desarrollo.
Kane Biotech는 2024년 3분기 동안 중요한 재무 결과를 보고하며 revyve™ Wound Gel의 첫 상업 판매를 기록했습니다. 총 수익은 1,282,698달러에 달하며, 2023년 3분기의 27,003달러에서 증가했습니다. 제품 판매는 597,677달러, 제품 서비스 수익은 685,021달러였습니다. 총 이익은 558,754달러로 증가하고, 순손실은 45% 감소하여 $(678,636)에 달했습니다. 회사는 여러 유통 계약을 체결하였고, revyve™ Antimicrobial Wound Gel에 대한 캐나다 보건부의 승인을 받았으며, FB Dermatology 인수 계획을 발표했습니다. 또한, Kane은 MDSAP 인증을 얻었고, 연구 및 개발 프로젝트를 위한 NRC IRAP 자금 275,000달러를 수상했습니다.
Kane Biotech annonce des résultats financiers significatifs pour le troisième trimestre 2024, marquant sa première vente commerciale de revyve™ Wound Gel. Le chiffre d'affaires total a atteint 1.282.698 dollars, en hausse par rapport à 27.003 dollars au troisième trimestre 2023, avec des ventes de produits s'élevant à 597.677 dollars et des revenus de services de produits de 685.021 dollars. Le bénéfice brut a augmenté à 558.754 dollars, tandis que la perte nette a diminué de 45 % pour atteindre $(678.636). L'entreprise a sécurisé plusieurs accords de distribution, a obtenu l'approbation de Santé Canada pour le revyve™ Antimicrobial Wound Gel et a annoncé des projets d'acquisition de FB Dermatology. De plus, Kane a reçu la certification MDSAP et a été attribué un financement NRC IRAP de 275.000 dollars pour des projets de recherche et développement.
Kane Biotech berichtet über bedeutende Finanzkennzahlen für das dritte Quartal 2024 und verzeichnet den ersten kommerziellen Verkauf von revyve™ Wound Gel. Der Gesamtumsatz betrug 1.282.698 Dollar, ein Anstieg von 27.003 Dollar im dritten Quartal 2023, mit Produkterlösen von 597.677 Dollar und Dienstleistungserlösen von 685.021 Dollar. Der Bruttogewinn stieg auf 558.754 Dollar, während der Nettoverlust um 45 % auf $(678.636) sank. Das Unternehmen sicherte sich mehrere Vertriebsvereinbarungen, erhielt die Genehmigung von Health Canada für revyve™ Antimicrobial Wound Gel und kündigte Pläne zur Akquisition von FB Dermatology an. Darüber hinaus erhielt Kane die MDSAP-Zertifizierung und erhielt eine NRC IRAP-Finanzierung in Höhe von 275.000 Dollar für Forschungs- und Entwicklungsprojekte.
- First commercial sale of revyve™ Wound Gel generating $594,705
- Total revenue increased significantly to $1,282,698 from $27,003 YoY
- Gross profit improved to $558,754 from $23,491 YoY
- Net loss reduced by 45% to $(678,636)
- Secured multiple international distribution agreements
- Received Health Canada approval for revyve™ Antimicrobial Wound Gel
- FDA removed usage limitation on revyve™ Antimicrobial Wound Gel
- Operating expenses increased 18% to $1,170,064
- Continuing operational losses of $(678,636)
Company Records First Commercial Sale of revyve™ Wound Gel
WINNIPEG, Manitoba, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its third quarter 2024 financial results.
Third Quarter 2024 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health “STEM” Operations):
- Product sales for the three months ended September 30, 2024 was
$597,677 compared to$3,631 in the three months ended September 30, 2023. During the third quarter, the Company recorded$594,705 from its first commercial sales of revyveTM Antimicrobial Wound Gel to its US distributor ProgenaCare. - Product services revenue for the three months ended September 30, 2024 was
$685,021 , an compared to $nil in the three months ended September 30, 2023. Product services revenue is derived from animal health manufacturing and quality control services that the Company is providing for a limited time post sale of STEM. - Total revenue for the three months ended September 30, 2024 was
$1,282,698 compared to$27,003 in the three months ended September 30, 2023. - Gross profit for the third quarter of 2024 was
$558,754 , compared to$23,491 for the third quarter of 2023. - Total operating expenses for the three months ended September 30, 2024 were
$1,170,064 , an increase of18% compared to$994,801 for the three months ended September 30, 2023. The increase is primarily due to higher employee compensation, consulting, travel and investor relations expenses recorded in the current period. - Net loss from continuing operations for the third quarter of 2024 was
$(678,636) , a decrease of45% compared to a net loss from continuing operations of ($1,244,099) for the quarter ending September 30, 2023.
Detailed financial information about Kane Biotech can be found in its September 30, 2024 Financial Statements and Management Discussion and Analysis on SEDAR and the Company’s website.
Recent Corporate Developments:
- On November 27, 2024, Kane Biotech announced that BioStem Technologies Inc. has recently signed a Letter of Intent to acquire commercial stage products and development technologies from the Company’s current U.S. distributor, ProgenaCare, including exclusive US distribution rights for Kane’s revyveTM Antimicrobial Wound Gel.
- On November 14, 2024, the Company announced that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This approval allows the Company to immediately start promoting and selling this product in Canada.
- On November 12, 2024, the Kane Biotech announced that it has entered into a binding term sheet setting out the key terms and conditions relating to the acquisition of all of the issued and outstanding shares of FB Dermatology incorporated under the laws of Italy. FB Dermatology currently has operations in Italy and Australia with product sales throughout Europe, Australia and New Zealand. The closing of the Acquisition is expected to occur on or about January 31, 2025.
- On October 23, 2024, the Company announced that it is donating 2,000 ounces of revyve™ Antimicrobial Wound Gel to the Ukraine medical relief effort. The product will be used to assist in the healing of severe and chronic wounds that tens of thousands of Ukrainian casualties have suffered as a result of the devastating effects of war.
- On October 17, 2024, the Company announced that it has signed an exclusive five-year distribution agreement with XSONX LLC (“XSONX”) for Kane to distribute XSONX’s Wound Hygiene System in Canada, Australia, New Zealand and the Gulf Cooperation Council (GCC) Countries. The XSONX Wound Hygiene System is a cordless vibrational debridement tool which safely cleans and debrides chronic and contaminated wounds. More information can be found at www.xsonx.com.
- On October 3, 2024, Kane Biotech announced that it is receiving advisory services and up to
$75,000 in funding through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to collaborate on a research and development project with a multinational corporate partner. The goal of the collaboration project is to develop a Proof-of Concept for its DispersinB® Wound Gel. Over a period of six months, Kane will be working closely on this project with one of the world’s largest wound care companies as its collaborator. - On September 12, 2024, the Company announced the exercise of an aggregate of five million warrants at an exercise price of
$0.10 per common share for total proceeds of$500,000. - On August 28, 2024, the Company announced that it had signed a three-year distribution agreement with Qatar Datamation Systems for its revyve™ Antimicrobial Wound Gel in the Qatar wound care market.
- On August 22, 2024, Kane Biotech announced that it had signed a three-year distribution agreement with Razan Medical & Surgical Equipment Trading LLC for its revyve™ Antimicrobial Wound Gel in the United Arab Emirates (UAE) wound care market.
- On August 13, 2024, Kane Biotech announced that it is receiving advisory services and up to
$200,000 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The funding will be received over a period of 20 months and will support the development of three additional products to build on Kane Biotech’s revyveTM Antimicrobial Wound Gel technology. The Company expects to be able to leverage its newly expanded FDA 510(k) clearance for its revyveTM Antimicrobial Wound Gel. - On July 23, 2024, Kane Biotech announced that the US FDA had eliminated its usage limitation on the Company’s 510(k) cleared revyve™ Antimicrobial Wound Gel. Prior to the removal of this restriction, there was a 90 grams/month limit to the amount of revyve™ product that could be administered to patients. This now clears the way for the introduction and extended use of Kane’s revyve™ Antimicrobial Wound Gel Spray which is expected to be filled in spray cans in a higher quantity making it ideal for application on large wounds.
- On July 17, 2024, Kane Biotech announced that it has received ISO 13485:2016 Medical Device Single Audit Program (“MDSAP”) Quality Certification as a designer, developer and manufacturer of medical devices. These standards require the existence of a comprehensive quality management system with a focus on areas directly impacting patient safety, product performance and reliability. Obtaining the ISO 13485:2016 MDSAP certification allows Kane to apply for regulatory approval of its revyve™ Antimicrobial Wound Gel in Canada, Australia, New Zealand and Brazil. MDSAP is an enhancement of Kane’s previous quality certification which enabled Kane to receive US Food and Drug Administration 510(k) clearance for revyve™.
- On July 11, 2024, Kane Biotech announced that it has signed a worldwide license agreement with Arizona-based Omni Bioceutical Innovations Inc. for its coactiv+™ line of scalp care products. The five-year non-exclusive agreement will see Omni commercialize Kane’s scalp detoxifier product under the Omni Bioceuticals brand in the medical aesthetics market
“In the third quarter we recorded our first commercial sale of revyveTM Antimicrobial Wound Gel, signed two new revyveTM Wound Gel product distribution agreements in the Middle East, received our MDSAP Quality Certification, and were awarded
The link to the Q3 2024 update video provided by Marc Edwards can be found here: Q3 2024 Update Video.
Conference Call
- Kane Biotech is pleased to invite all interested parties to participate in a conference call on Tuesday, December 3, 2024 at 4:30pm ET to review the financial results and discuss business developments in the period.
- Participants can access the live webcast link as follows: Conference call with Q&A or conference call listen only mode. A webcast of the call will be available on the Company's website at kanebiotech.com under "News/Events" in the Investors section of the Kane Biotech website at ir.kanebiotech.com.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. DispersinB®, Aledex™, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information:
| Marc Edwards | Ray Dupuis | |||
| Chief Executive Officer | Chief Financial Officer | |||
| Kane Biotech Inc | Kane Biotech Inc | |||
| medwards@kanebiotech.com | rdupuis@kanebiotech.com | |||
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
| KANE BIOTECH INC. | ||||||||||||||||
| Selected Financial Results | ||||||||||||||||
| Consolidated Statements of Comprehensive Income (Loss) | Three months ended September 30, | Nine months ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Total revenue, continuing operations | $ | 1,282,698 | $ | 27,003 | $ | 1,955,021 | $ | 91,192 | ||||||||
| Gross profit, continuing operations | 558,754 | 3,512 | 995,720 | 16,023 | ||||||||||||
| Operating expenses, continuing operations | ||||||||||||||||
| General and administration | 986,824 | 716,839 | 2,752,152 | 1,540,057 | ||||||||||||
| Research | 183,240 | 277,962 | 1,109,463 | 634,164 | ||||||||||||
| Total operating expenses, continuing operations | 1,170,064 | 994,801 | 3,861,615 | 2,174,221 | ||||||||||||
| Loss prior to other expenses, continuing operations | (611,310 | ) | (971,310 | ) | (2,902,314 | ) | (2,099,052 | ) | ||||||||
| Net other expenses, continuing operations | 67,326 | 272,789 | 486,104 | 940,871 | ||||||||||||
| Loss and comprehensive loss for the period, | ||||||||||||||||
| continuing operations | $ | (678,636 | ) | $ | (1,244,099 | ) | $ | (3,388,418 | ) | $ | (3,039,923 | ) | ||||
| Income (loss) and comprehensive income (loss) | ||||||||||||||||
| from discontinued operations | $ | 72,823 | $ | (201,471 | ) | $ | 10,637,610 | $ | (618,237 | ) | ||||||
| Net income (loss) and comprehensive income (loss) | ||||||||||||||||
| attributable to shareholders | $ | (605,813 | ) | $ | (1,378,401 | ) | $ | 7,180,877 | $ | (3,452,040 | ) | |||||
| Net income (loss) and comprehensive income (loss) | $ | (605,813 | ) | $ | (1,445,570 | ) | $ | 7,249,192 | $ | (3,658,160 | ) | |||||
| Basic income (loss) per share for the period | $ | (0.01 | ) | $ | (0.01 | ) | $ | 0.05 | $ | (0.04 | ) | |||||
| Weighted average shares outstanding - basic | 133,788,741 | 126,798,371 | 132,667,757 | 125,527,781 | ||||||||||||
| Consolidated Statements of Financial Position | September 30, | December 31 | ||||||||||||||
| 2024 | 2023 | |||||||||||||||
| Cash and cash equivalents | $ | 544,377 | $ | 749,248 | ||||||||||||
| Other current assets | 1,668,057 | 502,164 | ||||||||||||||
| Assets held-for-sale - current | - | 2,471,694 | ||||||||||||||
| Non-current assets | 1,692,938 | 1,799,008 | ||||||||||||||
| Assets held-for-sale - non-current | - | 158,805 | ||||||||||||||
| Total assets | $ | 3,905,372 | $ | 5,680,919 | ||||||||||||
| Current liabilities | $ | 2,759,962 | $ | 10,273,267 | ||||||||||||
| Liabilities held-for-sale - current | - | 621,133 | ||||||||||||||
| Non-current liabilities | 1,834,056 | 2,366,593 | ||||||||||||||
| Liabilities held-for-sale - non-current | - | 829,318 | ||||||||||||||
| Shareholders' deficit | (688,646 | ) | (8,409,392 | ) | ||||||||||||
| Total liabilities and shareholders' equity | $ | 3,905,372 | $ | 5,680,919 | ||||||||||||
FAQ
What was Kane Biotech's (KNBIF) revenue in Q3 2024?
How much was Kane Biotech's (KNBIF) first commercial sale of revyve™ Wound Gel?
What regulatory approvals did Kane Biotech (KNBIF) receive in 2024?
What was Kane Biotech's (KNBIF) net loss in Q3 2024?
